Search
for
Sort by
Research 211–240 of 1000+
- (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
- BH02 Reversibility of 5-alpha reductase inhibitor effects on semen parameters: a review of human evidence
- Fast Motions in 5 Alpha Reductase and Its Impact on Enzyme Kinetics
- Evidence of Increased 3‐Alpha‐Androstanediol Glucuronide in Female Pattern Alopecia: A Cross‐Sectional Observational Study Evaluating Ovarian, Adrenal, and Peripheral Androgens
- Impact of 5-alpha Reductase Inhibitors on Male Reproductive Health: A Review of Finasteride and Dutasteride.
- Intralesional methotrexate in patchy alopecia areata: trichoscopic evaluation and effect on lesional tumour necrosis factor alpha
- No Increased Cardiovascular Hazard with Oral 5-Alpha-Reductase Inhibitors in Treatment of Androgenetic Alopecia: A TriNetX Retrospective Cohort Study
- Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- GC-MS Fatty Acid Profile and In silico Studies of Telfairia occidentalis Hook f. (Fluted Pumpkin) and Sphenostylis stenocarpa (African Yam bean) Seeds Oil on Human 5 Alpha Reductase II
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- An isotope dilution-liquid chromatography-tandem mass spectrometry-based candidate reference measurement procedure for the quantification of 5-alpha-dihydrotestosterone in human serum and plasma
- Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
- Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
- No elevated risk for osteoporosis or osteopenia among women with androgenetic or frontal fribrosing alopecia treated with 5-alpha reductase inhibitors: A retrospective TriNetX cohort study
- Risk of Type 2 Diabetes Mellitus in New Users of 5-Alpha Reductase Inhibitors: A Nationwide Historical Cohort Study
- Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- Comparative Efficacy of Oral and Topical 5-Alpha Reductase Inhibitors in Reducing Dihydrotestosterone levels across Men with Androgenetic Alopecia: A Network Meta-Analysis incorporating Post-Hoc Analyses of Randomized Clinical Trial Data
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- A proprietary lipidosterolic extract of Serenoa repens promotes hair growth through mechanisms that extend beyond 5‐alpha reductase inhibition: Insights from human hair follicle organ culture
- SAT-279 The Effect of Chronic 5-alpha Reductase Inhibition on Clinically Apparent and Silent Cardiovascular Events
- An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
- Geographic Influence and Metabolomics-Driven Discovery of 5-Alpha Reductase Inhibitors in Tectona grandis L.f. (Teak) Leaves
- Comparative Efficacy of Minoxidil and 5‐Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta‐Analysis Study of Current Empirical Evidence
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- 5-Alpha Reductase Inhibitors on Hypersexuality During the Manic Phase of Bipolar and Psychotic Patients; New Insight to a Well-Known Medicines
- Risk associated with the use of 5-alpha reductase inhibitors with minoxidil in treatment of male androgenetic alopecia – literature review
- Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
- Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease
- 5-Alpha-Reductase Inhibitors in the Treatment of Male Androgenetic Alopecia: Clinical Experience